Skip to main content
U.S. flag

An official website of the United States government

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you’ve safely connected to the .gov website. Share sensitive information only on official, secure websites.

Search Publications by: John P. Marino (Fed)

Search Title, Abstract, Conference, Citation, Keyword or Author
Displaying 1 - 25 of 77

The emerging landscape of single-molecule protein sequencing technologies

April 11, 2023
Zvi Kelman, John Marino
Single-cell profiling methods have had a profound impact on the understanding of cellular heterogeneity. While genomes and transcriptomes can be explored at the single-cell level, single-cell profiling of proteomes is not yet established. Here we describe

Humanized Monoclonal Antibody IgG1k, NISTmAb RM 8671 Summary of 5 Year Stability Verification (5YSV)

March 31, 2023
Katharina Yandrofski, John E. Schiel, Trina Mouchahoir, Srivalli Telikepalli, N. Alan Heckert, Dean C. Ripple, Paul C. DeRose, Karen W. Phinney, John Marino
NISTmAb RM 8671 is an IgG1κ monoclonal antibody that has been extensively characterized and released as the first of its kind biopharmaceutical reference material in 2016. This material was intended primarily for use in evaluating the performance of

Backbone NMR assignment of the yeast produced Fab fragment of the NISTmAb reference antibody

March 1, 2023
Tsega Solomon, Kinlin Chao, Genevieve Gingras, Yves Aubin, William Brad O'Dell, John Marino, Robert Brinson
The monoclonal antibody (mAb) protein class has become a primary therapeutic platform for the production of new life saving drug products. MAbs are comprised of two domains: the antigen-binding fragment (Fab) and crystallizable fragment (Fc). Despite the

Structural Fingerprinting of siRNA Therapeutics by Solution NMR Spectroscopy

August 4, 2022
Owen Becette, Anh Tran, Jace Jones, John Marino, Robert Brinson
Nucleic acids are an increasingly popular platform for the development of biotherapeutics to treat a wide variety of illnesses, including diseases where traditional drug development efforts have failed. To date, there are 14 short oligonucleotide

Selective C-terminal Conjugation of Trypsin-Digested Peptides for Proteomic Measurements

July 20, 2022
Tian Xie, Alexandria Brady, Cecilia Velarde, David Vaccarello, Nicholas Callahan, John Marino, Sara Orski
Bottom-up proteomic experiments often require selective conjugation or labeling of the N- and/or C-termini of peptides either through bottom up approaches or selective post-cleavage functionalization of specific residues after proteolytic digestion . For

Interlaboratory Studies using the NISTmAb to Advance Biopharmaceutical Structural Analytics

May 5, 2022
Katharina Yandrofski, Trina Mouchahoir, M. Lorna De Leoz, David L. Duewer, Jeffrey W. Hudgens, Kyle Anderson, Luke Arbogast, Frank Delaglio, Robert Brinson, John Marino, Karen W. Phinney, Michael J. Tarlov, John E. Schiel
Biopharmaceuticals such as monoclonal antibodies are required to be rigorously characterized using a wide range of analytical methods. Various material properties must be characterized and well controlled to assure that clinically relevant features and

Excipient Innovation Through Precompetitive Research

December 20, 2021
Bruce Yu, Marc Taraban, Katharine Briggs, Robert Brinson, John Marino
The mRNA COVID-19 vaccines developed by Pfizer/BioNTech and Moderna represent a triumph of vaccine development. The core mRNA component of these vaccines is now almost a household name. Unbeknownst to most people, however, is that each of the two mRNA

Highly conserved s2m element of SARS-CoV-2 dimerizes via a kissing complex and interacts with host miRNA-1307-3p

December 1, 2021
Joshua A. Imperatore, Caylee L. Cunningham, Kendy A. Pellegrene, Robert Brinson, John Marino, Jeffery D. Evanseck, Mihaela R. Mihailescu
The ongoing COVID-19 pandemic highlights the necessity for a more fundamental understanding of the coronavirus life cycle. The causative agent of the disease, SARS-CoV-2, is being studied extensively from a structural standpoint in order to gain insight

Grand Challenges in Pharmaceutical Research Series: Ridding the Cold Chain for Biologics

February 8, 2021
Yihua B. Yu, Katharine T. Briggs, Marc B. Taraban, Robert Brinson, John Marino
Biologics are complex pharmaceuticals that include formulated proteins, plasma products, vaccines, cell and gene therapy products, and biological tissues. These products are fragile and typically require cold chain for their delivery and storage

Principal Component Analysis for Automated Classification of 2D Spectra and Interferograms of Protein Therapeutics: Influence of Noise, Reconstruction Details, and Data Preparation

July 22, 2020
Robert Brinson, Wade Elliott, Luke Arbogast, David Sheen, John Giddens, John Marino, Frank Delaglio
Protein therapeutics must retain their proper three-dimensional fold without forming aggregates for safe and effective use in the clinic. Therefore, the ability to monitor protein higher order structure (HOS) can be valuable throughout the lifecycle of a

Strategies for Development of a Next-Generation Protein Sequencing Platform

January 1, 2020
Nicholas Callahan, Jennifer A. Tullman, John Marino, Zvi Kelman
Proteomic analysis can be a critical bottleneck in cellular characterization. The current paradigm relies primarily on mass spectrometry of peptides and affinity reagents (i.e. antibodies), both of which require a priori knowledge of the sample. A non

Engineering ClpS for Selective and Enhanced N-terminal Amino Acid Binding

March 1, 2019
Jennifer A. Tullman, Zvi Kelman, John P. Marino
One of the central challenges in the development of single-molecule protein sequencing technologies is achieving high-fidelity, sequential recognition and detection of specific amino acids that comprise the peptide sequence. An approach towards achieving

Enabling adoption of 2D-NMR for the higher order structure assessment of monoclonal antibody therapeutics

January 1, 2019
Robert G. Brinson, John P. Marino, Frank Delaglio, Luke W. Arbogast, Ryan M. Evans, Anthony J. Kearsley, Yves Aubin, Gregory Pierens, Xinying Jia, David Keizer, Jonas Stahle, Goran Widmalm, Chad Lawrence, Patrick Reardon, John Cort, Koichi Kato, Stuart Parnham, Andreas Blomgren, Torgny Rundlof, Kang Chen, David Keire, Thea Suter-Stahel, Gerhard Wider, Donna Baldisseri, Julie Wu, Mats Wikstrom, Medhi Mobli
Of the top ten drugs on the global market in 2016, seven of them are biologics with a combined market value of over US$60 billion. Moreover, around 2,800 biopharmaceuticals, many of them monoclonal antibodies (mAbs), are in some stage of clinical